Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
antigens
breast neoplasms
neoplasm
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
10
05
2021
entrez:
26
6
2021
pubmed:
27
6
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cell identification and validation program that supports the development of next-generation immunotherapies. Using GPS Cancer, NantOmics research, and The Cancer Genome Atlas databases, we developed a novel bioinformatic-based approach which assesses mutational load, neoepitope expression, human leukocyte antigen (HLA)-binding prediction, and in vitro confirmation of T-cell recognition to preferentially identify targetable neoepitopes. This program was validated by application to a BC cell line and confirmed using tumor biopsies from two patients with BC enrolled in the Tumor-Infiltrating Lymphocytes and Genomics (TILGen) study. The antigenicity and HLA-A2 restriction of the BC cell line predicted neoepitopes were determined by reactivity of T cells from HLA-A2-expressing healthy donors. For the TILGen subjects, tumor-infiltrating lymphocytes (TILs) recognized the predicted neoepitopes both as peptides and on retroviral expression in HLA-matched Epstein-Barr virus-lymphoblastoid cell line and BC cell line MCF-7 cells; PCR clonotyping revealed the presence of T cells in the periphery with T-cell receptors for the predicted neoepitopes. These high-avidity immune responses were polyclonal, mutation-specific and restricted to either HLA class I or II. Interestingly, we observed the persistence and expansion of polyclonal T-cell responses following neoadjuvant chemotherapy. We demonstrate our neoepitope prediction program allows for the successful identification of neoepitopes targeted by TILs in patients with BC, providing a means to identify tumor-specific immunogenic targets for individualized treatment, including vaccines or adoptively transferred cellular therapies.
Sections du résumé
BACKGROUND
Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cell identification and validation program that supports the development of next-generation immunotherapies.
METHODS
Using GPS Cancer, NantOmics research, and The Cancer Genome Atlas databases, we developed a novel bioinformatic-based approach which assesses mutational load, neoepitope expression, human leukocyte antigen (HLA)-binding prediction, and in vitro confirmation of T-cell recognition to preferentially identify targetable neoepitopes. This program was validated by application to a BC cell line and confirmed using tumor biopsies from two patients with BC enrolled in the Tumor-Infiltrating Lymphocytes and Genomics (TILGen) study.
RESULTS
The antigenicity and HLA-A2 restriction of the BC cell line predicted neoepitopes were determined by reactivity of T cells from HLA-A2-expressing healthy donors. For the TILGen subjects, tumor-infiltrating lymphocytes (TILs) recognized the predicted neoepitopes both as peptides and on retroviral expression in HLA-matched Epstein-Barr virus-lymphoblastoid cell line and BC cell line MCF-7 cells; PCR clonotyping revealed the presence of T cells in the periphery with T-cell receptors for the predicted neoepitopes. These high-avidity immune responses were polyclonal, mutation-specific and restricted to either HLA class I or II. Interestingly, we observed the persistence and expansion of polyclonal T-cell responses following neoadjuvant chemotherapy.
CONCLUSIONS
We demonstrate our neoepitope prediction program allows for the successful identification of neoepitopes targeted by TILs in patients with BC, providing a means to identify tumor-specific immunogenic targets for individualized treatment, including vaccines or adoptively transferred cellular therapies.
Identifiants
pubmed: 34172517
pii: jitc-2021-002605
doi: 10.1136/jitc-2021-002605
pmc: PMC8237736
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Science. 2014 Jan 10;343(6167):152-7
pubmed: 24310608
BMC Cancer. 2012 Mar 20;12:96
pubmed: 22433494
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nucleic Acids Res. 2015 Jan;43(Database issue):D423-31
pubmed: 25414341
Breast Cancer Res. 2017 Aug 7;19(1):91
pubmed: 28784153
Clin Cancer Res. 2014 Jun 1;20(11):2831-7
pubmed: 24879823
Onco Targets Ther. 2020 Mar 31;13:2657-2666
pubmed: 32308409
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Front Oncol. 2020 Oct 27;10:605633
pubmed: 33194771
BMC Cancer. 2018 Nov 8;18(1):1082
pubmed: 30409126
Pathologe. 2018 Dec;39(Suppl 2):236-240
pubmed: 30406831
J Clin Oncol. 2016 Sep 10;34(26):3204-12
pubmed: 27432922
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Biotechnol. 2019 Nov;37(11):1332-1343
pubmed: 31611695
J Virol. 2002 Oct;76(20):10219-25
pubmed: 12239297
Curr Oncol Rep. 2018 Apr 30;20(7):51
pubmed: 29713831
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Clin Exp Metastasis. 2008;25(6):629-42
pubmed: 18461285
Sci Rep. 2018 Aug 24;8(1):12735
pubmed: 30143704
Nat Commun. 2018 May 14;9(1):1894
pubmed: 29760388
Bioinformatics. 2008 Jun 1;24(11):1397-8
pubmed: 18413329
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12
pubmed: 18463140
Front Immunol. 2020 Mar 11;11:381
pubmed: 32218783
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000
pubmed: 26286987
J Immunol. 2016 Feb 15;196(4):1480-7
pubmed: 26783342
J Clin Oncol. 2017 Jul 20;35(21):2450-2456
pubmed: 28640704
Cancer Res. 1976 Dec;36(12):4562-9
pubmed: 1000501
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Cancer Immunol Res. 2019 Aug;7(8):1359-1370
pubmed: 31292145
Nat Biotechnol. 2018 Dec 17;:
pubmed: 30556813
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Nat Cell Biol. 2012 Feb 19;14(3):318-28
pubmed: 22344029
Annu Rev Immunol. 2013;31:443-73
pubmed: 23298205
Cancer Res. 2008 Feb 1;68(3):889-92
pubmed: 18245491
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
J Natl Compr Canc Netw. 2018 Oct;16(10):1259-1268
pubmed: 30323094
Methods Mol Biol. 2017;1532:57-64
pubmed: 27873266
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nature. 2016 Aug 4;536(7614):91-5
pubmed: 27350335
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
J Clin Oncol. 2015 Jun 1;33(16):1745-53
pubmed: 25918295
Clin Cancer Res. 2017 Jun 1;23(11):2640-2646
pubmed: 28572258
Haematologica. 2014 Feb;99(2):365-9
pubmed: 24097630
Eur J Immunol. 1993 Jun;23(6):1215-9
pubmed: 7684681
Breast Care (Basel). 2018 Mar;13(1):8-14
pubmed: 29950961